ProCE Banner Activity

CAPTIVATE: 5-Yr Follow-up of Continued Ibrutinib vs Placebo in Patients With CLL/SLL and Undetectable MRD After First-line Ibrutinib + Venetoclax

Slideset Download
Conference Coverage

First-line ibrutinib + venetoclax showed ongoing efficacy in patients with CLL/SLL through a median follow-up of 56 months, with 3-year disease-free survival rates of 93% and 85% in patients with confirmed undetectable MRD receiving continued ibrutinib vs placebo, respectively.

Released: December 14, 2022

Expiration: December 13, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen